Stocks Overview

LAST PRICE
42.7500
TODAY'S CHANGE (%)
Trending Up0.2800 (0.6593%)

Bid / Lots
42.5000/ 1
Ask / Lots
43.0000/ 16
Open / Previous Close
42.4900 / 42.4700
Day Range
Low 42.3800
High 42.8450
52 Week Range
Low 19.5900
High 43.5898
Volume
714,167
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Friday's close: 42.47
Time	Volume	CERE
09:32 ET	6481	42.48
09:34 ET	3070	42.46
09:36 ET	1100	42.49
09:38 ET	1548	42.445
09:39 ET	956	42.425
09:41 ET	300	42.435
09:43 ET	1298	42.46
09:45 ET	439	42.46
09:48 ET	567	42.475
09:50 ET	1700	42.495
09:52 ET	300	42.49
09:54 ET	1573	42.55
09:56 ET	1200	42.54
09:57 ET	400	42.555
09:59 ET	1100	42.615
10:01 ET	2493	42.59
10:03 ET	1032	42.64
10:06 ET	1700	42.62
10:08 ET	1100	42.635
10:10 ET	1400	42.645
10:12 ET	4448	42.65
10:14 ET	2200	42.645
10:15 ET	2674	42.655
10:17 ET	1339	42.655
10:19 ET	2300	42.65
10:21 ET	1426	42.635
10:24 ET	200	42.635
10:26 ET	1900	42.59
10:28 ET	2800	42.595
10:30 ET	2037	42.625
10:32 ET	800	42.635
10:35 ET	3200	42.625
10:37 ET	1100	42.615
10:39 ET	1200	42.585
10:42 ET	700	42.585
10:44 ET	500	42.585
10:46 ET	700	42.585
10:48 ET	1699	42.595
10:50 ET	653	42.595
10:51 ET	3153	42.54
10:53 ET	15942	42.475
10:55 ET	7268	42.485
10:57 ET	1442	42.46
11:00 ET	3456	42.385
11:02 ET	5816	42.405
11:04 ET	2888	42.425
11:06 ET	1948	42.405
11:08 ET	4186	42.415
11:09 ET	600	42.42
11:11 ET	1500	42.435
11:13 ET	1924	42.465
11:15 ET	600	42.445
11:18 ET	300	42.47
11:20 ET	1083	42.485
11:22 ET	2709	42.46
11:24 ET	1800	42.47
11:26 ET	300	42.465
11:27 ET	2700	42.44
11:29 ET	1373	42.47
11:31 ET	5471	42.475
11:33 ET	10806	42.56
11:36 ET	2100	42.525
11:38 ET	1700	42.5
11:40 ET	2601	42.505
11:42 ET	9300	42.5
11:44 ET	2600	42.52
11:45 ET	6200	42.53
11:47 ET	700	42.52
11:49 ET	700	42.54
11:51 ET	700	42.55
11:54 ET	900	42.555
11:56 ET	200	42.555
11:58 ET	1600	42.57
12:00 ET	200	42.585
12:02 ET	800	42.585
12:03 ET	6388	42.625
12:05 ET	1863	42.625
12:07 ET	400	42.625
12:09 ET	1233	42.625
12:12 ET	2544	42.635
12:14 ET	660	42.635
12:16 ET	200	42.635
12:20 ET	5205	42.625
12:21 ET	300	42.625
12:23 ET	12177	42.605
12:25 ET	1860	42.63
12:27 ET	200	42.635
12:30 ET	300	42.635
12:32 ET	2700	42.61
12:34 ET	800	42.625
12:36 ET	474	42.635
12:38 ET	3210	42.64
12:39 ET	1467	42.638
12:41 ET	1343	42.655
12:43 ET	900	42.66
12:45 ET	500	42.665
12:48 ET	1200	42.68
12:50 ET	5277	42.735
12:52 ET	2700	42.75
12:54 ET	2200	42.69
12:56 ET	1977	42.66
12:57 ET	2170	42.655
12:59 ET	300	42.67
01:01 ET	200	42.675
01:03 ET	400	42.675
01:06 ET	1293	42.685
01:08 ET	8182	42.71
01:10 ET	2700	42.71
01:12 ET	2000	42.72
01:14 ET	4100	42.765
01:15 ET	4138	42.785
01:17 ET	4036	42.79
01:19 ET	9244	42.77
01:21 ET	2524	42.78
01:24 ET	400	42.775
01:26 ET	1200	42.775
01:28 ET	300	42.775
01:30 ET	700	42.76
01:32 ET	300	42.75
01:33 ET	200	42.755
01:35 ET	300	42.755
01:37 ET	339	42.745
01:39 ET	400	42.745
01:42 ET	400	42.745
01:44 ET	770	42.735
01:46 ET	1205	42.72
01:48 ET	300	42.725
01:50 ET	7215	42.805
01:51 ET	2033	42.805
01:53 ET	300	42.805
01:55 ET	100	42.805
01:57 ET	300	42.81
02:00 ET	2602	42.835
02:02 ET	900	42.81
02:04 ET	500	42.815
02:06 ET	1231	42.795
02:08 ET	200	42.795
02:09 ET	910	42.79
02:11 ET	6157	42.81
02:13 ET	610	42.81
02:15 ET	658	42.8025
02:18 ET	500	42.805
02:20 ET	3110	42.8
02:24 ET	300	42.805
02:26 ET	6561	42.77
02:27 ET	200	42.77
02:29 ET	600	42.7625
02:31 ET	4818	42.73
02:33 ET	11412	42.705
02:36 ET	3400	42.71
02:38 ET	4317	42.7098
02:40 ET	1200	42.705
02:42 ET	200	42.705
02:44 ET	400	42.7025
02:45 ET	2818	42.7
02:47 ET	400	42.705
02:49 ET	8867	42.7
02:51 ET	900	42.705
02:54 ET	400	42.705
02:56 ET	1400	42.715
02:58 ET	2100	42.715
03:02 ET	6458	42.705
03:03 ET	36269	42.7
03:05 ET	200	42.695
03:07 ET	2700	42.685
03:09 ET	3576	42.685
03:12 ET	4712	42.67
03:14 ET	3961	42.615
03:16 ET	3734	42.63
03:18 ET	1748	42.615
03:20 ET	1800	42.63
03:21 ET	700	42.65
03:23 ET	1100	42.65
03:25 ET	1600	42.635
03:27 ET	500	42.625
03:30 ET	600	42.625
03:32 ET	1234	42.62
03:34 ET	2027	42.655
03:36 ET	1000	42.655
03:38 ET	3614	42.71
03:39 ET	300	42.72
03:41 ET	1855	42.705
03:43 ET	1600	42.73
03:45 ET	2512	42.71
03:48 ET	700	42.7
03:50 ET	800	42.705
03:52 ET	9387	42.705
03:54 ET	9147	42.705
03:56 ET	4487	42.73
03:57 ET	7674	42.7
03:59 ET	37688	42.75

Data delayed at least 15 minutes.

Apr 18, 2024
- DJ AbbVie's Bet on a Neuroscience Drug Maker Just Got Better -- Heard on the Street -- WSJ, from 12:17PM ET on Thursday Apr 18, 2024 by Dow Jones
  12:17PM ET on Thursday Apr 18, 2024 by Dow Jones
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease, from 6:30AM ET on Thursday Apr 18, 2024 by Dow Jones
  6:30AM ET on Thursday Apr 18, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesCERE Cerevel Therapeutics Holdings Inc	7.7B	-16.1x	---
United StatesVKTX Viking Therapeutics Inc	8.2B	-81.1x	---
United StatesCYTK Cytokinetics Inc	6.8B	-11.5x	---
United StatesPCVX Vaxcyte Inc	6.6B	-15.0x	---
United StatesRVMD Revolution Medicines Inc	5.9B	-9.8x	---
United StatesLEGN Legend Biotech Corp	8.2B	-15.3x	---
As of 2024-04-29

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.

Contact Information

Headquarters: 222 Jacobs Street, Suite 200CAMBRIDGE, MA, United States 02141
Phone: 212-284-2300
Fax: 302-636-5454

Executives

Chairperson of the Board of Directors: N. Coles
President, Chief Executive Officer, Member of the Board: Ronald Renaud
Chief Financial Officer: Susan Altschuller
Chief Human Resources Officer: Kenneth Dipietro
Senior Vice President - Finance, Chief Accounting Officer: Mark Bodenrader

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$7.7B
Revenue (TTM)	$0.00
Shares Outstanding	181.6M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.48
EPS	$-2.66
Book Value	$3.71
P/E Ratio	-16.1x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Cerevel Therapeutics Holdings Inc
NASDAQ:CEREUnited States

Search Criteria

Charts

Recent News

Apr 18, 2024

DJ AbbVie's Bet on a Neuroscience Drug Maker Just Got Better -- Heard on the Street -- WSJ, from 12:17PM ET on Thursday Apr 18, 2024 by Dow Jones

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease, from 6:30AM ET on Thursday Apr 18, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar